Enhancing the Development Pipeline through Strategic Alliances with Companies in Japan and Overseas
First written in FY2017. 6 of 9 entries say "Advanced", first in FY2018. Latest entry: 2026-03-24.
The whole theme swung hardest in 2025: 1 of 11 companies on the "Worse" side.
9 other companies' latest entry also says "Advanced".
- 2026-03-24AdvancedOther Disclosures
「We are pleased to announce that the two companies have agreed to jointly develop multiple product candidates in the women’s healthcare field and have entered into an agreement.」
The strategic collaboration with Gedeon Richter has taken concrete form through the execution of an agreement to jointly develop multiple women’s healthcare product candidates. - FY2022AdvancedAnnual report
「For biosimilars, we are jointly developing 6 products with Alvotech, preparing an application for approval for 1 of them, and discussing 1 additional product.」
Describes the development stages: joint development with Alvotech has expanded from 5 to 6 products, with 1 product in preparation for a regulatory application and 1 additional product under discussion. - FY2021AdvancedAnnual report
「For biosimilars, we are jointly developing 5 products with Alvotech and discussing 2 additional products.」
Describes the specific status of the development pipeline under the partnership with Alvotech: joint development of 5 products is continuing, and 2 additional products are under discussion. - FY2020AdvancedAnnual report
「For biosimilars, we have begun joint development with Alvotech of 5 products.」
Describes specific progress in enhancing the development pipeline through strategic partnerships, with joint development of 5 products having begun with Alvotech. - FY2019-Q3RestatedAnnual report
「On 16 December 2018, we agreed with Alvotech hf, a member of the Alvogen Group, on an exclusive partnership for the commercialization in Japan of multiple biosimilars and decided to acquire an equity interest in Alvotech HD in order to further deepen the relationship between the two companies.」
Continues to describe the exclusive partnership with Alvotech hf for the commercialization in Japan of multiple biosimilars and the equity investment in Alvotech HD. - FY2019-Q2RestatedAnnual report
「On 16 December 2018, we agreed with Alvotech hf, a member of the Alvogen Group, on an exclusive partnership for the commercialization in Japan of multiple biosimilars and decided to acquire an equity interest in Alvotech HD in order to further deepen the relationship between the two companies.」
Continues to describe the exclusive partnership with Alvotech hf for the sale of multiple biosimilars in Japan and the equity investment in Alvotech HD. - FY2019-Q1AdvancedAnnual report
「On 16 December 2018, we agreed with Alvotech hf on an exclusive partnership for the commercialization in Japan of multiple biosimilars and decided to acquire an equity interest in Alvotech HD in order to further deepen the relationship between the two companies.」
Describes specific progress in enhancing the development pipeline through strategic partnerships, including an exclusive partnership with Alvotech hf for the commercialization of multiple biosimilars in Japan and an equity investment in Alvotech HD. - FY2018AdvancedAnnual report
「We have agreed with Alvotech hf on an exclusive partnership for the commercialization in Japan of multiple biosimilars, and have now agreed to acquire an equity interest in Alvotech HD in order to further deepen the relationship between the two companies.」
Describes the enhancement of the development pipeline through strategic partnerships, including an exclusive partnership with Alvotech hf for the commercialization in Japan of multiple biosimilars and an equity investment to strengthen the relationship. - FY2017First statedAnnual report
「Enhancing the pipeline (products under development) through strategic partnerships with domestic and overseas companies」
Explicitly identifies expanding products under development through strategic partnerships with other companies as one of the issues to address.